Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study

Abstract

AbstractAimTo evaluate the efficacy and safety of insulin glargine 300 U/mL (Gla‐300) in people with suboptimally controlled type 2 diabetes (T2D) in China.MethodsINITIATION (NCT05002933) was a prospective, interventional, multicentre, single‐arm, phase IV study conducted in China. Individuals with suboptimally controlled T2D who were insulin naïve or switching from another basal insulin (insulin experienced) were included. The primary endpoint was the change in HbA1c from baseline to week 24. Safety assessments included hypoglycaemia and adverse events (AEs).ResultsIn total, 568 participants were enrolled and 562 initiated Gla‐300 treatment (189 in the insulin‐naïve subgroup; 373 in the insulin‐experienced subgroup). At week 24, the mean ± standard error (SE) change in HbA1c from baseline was −0.91% ± 0.05% (−9.9 ± 0.5 mmol/mol; P < .0001). Significant HbA1c reductions were also observed in the insulin‐naïve (mean ± SE change: −1.38% ± 0.09% [−15.1 ± 1.0 mmol/mol]) and insulin‐experienced (−0.68% ± 0.05% [−7.4 ± 0.5 mmol/mol]) subgroups (both P < .0001). During the 24‐week treatment period, the incidence of confirmed hypoglycaemia (plasma glucose ≤ 3.9 mmol/L) was 39.7% for all hypoglycaemia and 13.3% for nocturnal hypoglycaemia; the incidence of severe hypoglycaemia was low (0.5%). Overall, treatment‐emergent AEs (TEAEs) were reported in 126 participants (22.4%), with no serious treatment‐related TEAEs.ConclusionsGla‐300 was effective in improving glycaemic control and had a relatively low risk of hypoglycaemia in people with suboptimally controlled T2D who were insulin naïve or switching from another basal insulin in China.